

SPHHP Research Activities Newsletter

University at Buffalo


August 2020

IN THE NEWS

Congratulations to the Following Awardees!



Jo Freudenheim, SUNY Distinguished Professor and Chair of Epidemiology and Environmental Health, is PI on a continuation award from the National Cancer Institute/NIH for the project entitled, *Interdisciplinary Training in Cancer Epidemiology at UB*. The program provides training and hands-on opportunities for pre-doctoral and post-doctoral fellows to develop research skills in epidemiology, as well as other related disciplines.



Keiona Nance, MS student in the Athletic Training Program/Exercise and Nutrition Sciences, received a new fellowship award from NATA Research and Education Foundation for the project entitled, *The Effect of Water Stirring on Cold Water Immersion Cooling Rates*. The study will examine whether the core body temperature of exertional heat stroke patients cool at a rate similarly with/without stirring in a cold water immersion. If the rates are similar, medical personnel could treat patients without stirring; thereby allowing them to complete other vital duties and improving patient outcomes. **Riana Pryor**, Assistant Professor of Exercise & Nutrition Sciences, serves as Ms. Nance's mentor.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, is PI on a new award from Kaleida Health for the project entitled, *ECRIP Role of Weight Management in Cancer Outcomes*. This project will train clinical research fellows through participation in outcomes research including other related disciplines and skills: qualitative and quantitative methods, clinical epidemiology, analysis of large administrative and clinical databases, implementation and dissemination science.

Dr. Noyes also is Curriculum Director on a continuation award from the National Heart, Lung, and Blood Institute/NIH (PIs: Ranjit Singh and John Canty, Medicine) for the project entitled, *UB Clinical Scholar Program in Implementation Science to Achieve Triple Aims*. The program trains and prepares clinician scientists for academic leadership and independent research careers in dissemination and implementation science related to heart, lung, blood, and sleep disorders with associated risk factors and complexities.



Heather Orom, Associate Professor of Community Health and Health Behavior, is Co-I on a new award from the National Center for Advancing Translational Sciences/NIH (PI: Timothy Murphy, Medicine) for the project entitled, *Igniting Hope: Mobilizing Community Resources to Achieve Health Equity 2020*. In partnership with the African American Health Equity Task Force (AAHETF), the award will fund an annual community-based multidisciplinary conference entitled the *Igniting Hope* series with a goal to continue the dialogue on developing a strategy, which builds a culture of health as the cornerstone of a plan to end health disparities among African Americans in Buffalo.



Jean Wactawski-Wende, Dean of SPHHP and SUNY Distinguished Professor of Epidemiology and Environmental Health (EEH), is PI on two continuation awards from Kent Memorial County Hospital for the projects entitled, *WHISH-2 Prevent Heart Failure Study* and *WHISH-2 Prevent Heart Failure Study Outcomes*. An ancillary study to the WHI, the projects will evaluate physical activity, sedentary behavior, muscle strength and the risk of heart failure. **Michael LaMonte**, Research Associate Professor of EEH, is Co-Investigator.

Inside this issue:

In the News	1-2
Grant Clinic	2-4
NIH Funding	
Limited	4
RFA	4-8
PAR	8-9
Individual Actions of Sustainability	9



Gregory Wilding, Professor and Chair of Biostatistics, is Co-I on a continuation award from the National Institute of Dental & Craniofacial Research/NIH (PI: Michelle Visser, Oral Biology) for the project entitled, *The Role of Oral Spirochete Virulence Factors in the Impairment of Neutrophil Response*. The study seeks to understand how oral treponemese modulate neutrophil response leads to periodontal disease and the development of potentially active therapeutic molecules will lead to the improvement of oral and systemic health.

GRANT CLINIC

General Notices

[NOT-OD-20-155](#)

eRA Enhancement: Change in Format to the Notice of Award Starting October 1, 2020

Starting on October 1, 2020, recipients will see a new standardized Page One of the Notice of Award (NoA). The NoA is the legal document issued to notify the recipient that an award has been made and that funds may be requested from the designated HHS payment system or office. This enhancement is part of HHS's Reinvent Grants Management initiative to standardize the NoA across various HHS systems and reduce the burden on recipients.

Policy Notices

[NOT-OD-20-158](#)

Temporary Extension of Eligibility for the NIH K99/R00 Pathway to Independence Award During the COVID-19 Pandemic

Under normal circumstances, individuals must have no more than four years of postdoctoral research experience to be eligible to apply for a K99/R00 Pathway to Independence award. The purpose of this notice is to inform the extramural community that due to disruptions caused by the COVID-19 pandemic, NIH will be providing up to a two-receipt cycle extension (roughly eight additional months) of eligibility for prospective applicants meeting the requirements for submission of a K99/R00 application from the time period covered by the June/July 2020 due dates through the February/March 2021 due dates.

[NOT-OD-20-163](#)

Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic

This Notice extends the special exception for post-submission material (see [NOT-OD-20-123](#)) to applications submitted for the May 2021 Council round. For applications submitted for the May 2021 council (beginning with applications submitted for the September 25, 2020 due date for Spring 2021 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application. One page of preliminary data will be accepted for single component applications or for each component of a multi-component application. The deadline for submitting all post-submission materials will be 30 days before the study section meeting.

Request for Information

[NOT-DA-20-073](#)

Advancing Biomarker Research and Implementation to Personalize Health Services Delivery for Tobacco Use Disorder

To address the barriers in biomarker research and implementation, NIDA is requesting information from clinical scientists engaging in biomarker discovery research; health care providers who provide services for TUD; and SUD health services researchers who study the implementation of innovations. TUD is a focus of this RFI due to its advanced position in regard to available treatments among all SUDs. **Responses must be received by 11:59:59 pm (ET) on October 1, 2020. All comments must be submitted electronically to NIDAbiomarker@nih.gov.**

Notice of Intent to Publish a Funding

[NOT-CA-20-086](#)

Notice of Intent to Publish a Funding Opportunity Announcement for New Cohorts to Assess Environmental Exposures and Cancer Risk (Clinical Trial Optional)

NCI intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for innovative scientific research to address knowledge gaps between environmental exposures and cancer etiology across diverse populations using new prospective cohort studies, which will be facilitated by a Coordinating Center that

is expected to be awarded under a separate RFA (see the parallel notice of intent to publish announcement [NOT-CA-20-091](#)). The Cohorts for Environmental Exposures and Cancer Risk (CEEER) will provide scientific evidence related to environmental exposures and cancer risk. The CEEER will be supported through UG3/UH3 phased awards. Approximately five new prospective cohorts are expected to be awarded.

[NOT-CA-20-091](#)

Notice of Intent to Publish a Funding Opportunity Announcement for a Coordinating Center for New Cohorts to Assess Environmental Exposures and Cancer Risk (U24 Clinical Trial Not Allowed)

NCI intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for a Coordinating Center to facilitate coordination across approximately five cohorts that are expected to be awarded under a separate RFA (see the parallel notice of intent to publish announcement [NOT-CA-20-086](#)). The Coordinating Center will be supported by a U24 award. The FOA is expected to use the U24 activity codes for the Coordinating Center (Clinical Trials Not Allowed). The FOA is expected to be published in November 2020 with an expected application due date in January 2021.

[NOT-DA-20-071](#)

Notice of Intent to Publish a HEAL Funding Opportunity Announcement for Consortium on Co-managing Chronic Pain and Opioid Use Disorder (C3PO) (RM1)

NIH intends to publish two Funding Opportunity Announcements (FOA) to solicit applications to build a network of researchers to develop sustainable evidence-based interventions to effectively treat non-cancer chronic pain (CP) and opioid use disorder (OUD). This network will be part of the of the NIH's Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This FOA is expected to use a collaborative program grant mechanism (RM1). The FOA is expected to be published in November 2020 with an expected application due date in January/February 2021.

Notice of Special Interests

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-AG-20-038](#)

Notice of Special Interest: Sex and Gender Differences in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)

This Notice of Special Interest (NOSI) is intended to promote multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD are also relevant. Submit applications for this initiative using [PAR-19-070](#) and [PAR-19-071](#). **Applicants must include "NOT-AG-20-038" in box 4B of the SF424 R&R form. First Available Due Date:** November 12, 2020 **Expiration Date:** November 13, 2021

[NOT-AG-20-040](#)

Notice of Special Interest: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer's Disease and Related Dementias (AD/ADRD)

This Notice of Special Interest (NOSI) is intended to underscore NIA's continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and AD-related dementias (ADRD). NIA also seeks to understand how changes in the structure and function of neurobiological and neuromodulatory systems mediate or moderate affective, motivational, and social behaviors and interact with other psychological functions, including cognition. Check the website for a list of applicable FOAs. **Applicants must include "NOT-AG-20-040" in box 4B of the SF424 R&R form.**

[NOT-AA-20-018](#)

Secondary Analyses of Existing Alcohol Research Data

The purpose of NOSI is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research. Check the website for a list of applicable FOAs. **Applicants must include "NOT-AA-20-018" in box 4B of the SF424 R&R form.**

[NOT-MD-20-026](#)

Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations

The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations. Submit applications for this initiative using [PA-20-183](#) and [PA-20-185](#). **Applicants must include "NOT-MD-20-026" in box 4B of the SF424 R&R form.**

[NOT-AA-20-019](#)

Alcohol and Aging

The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. Check the website for a list of applicable FOAs. **Applicants must include "NOT-AA-20-019" in box 4B of the SF424 R&R form.**

NIH FUNDING OPPORTUNITIES

LIMITED SUBMISSIONS

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. As of August 8, 2019, the Limited Submission Program is being managed by Dr. Joseph Balthasar, Executive Director of Research Initiatives, on behalf of the OVPRED. He may be contacted at jb@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-AG-21-009 \(P30\)](#) clinical trial optional

Artificial Intelligence and Technology Collaboratories for Aging Research

The AITC program will serve as a national resource to promote the development and implementation of artificial intelligence approaches and technology through demonstration projects to improve care and health outcomes for older Americans, including persons with dementia (PWD) and their caregivers. *Only one application per institution is allowed.* **Application Due Date:** October 1, 2020

REQUESTS FOR APPLICATIONS (RFA)

October Due Dates

[RFA-AG-21-015 \(U19\)](#) clinical trial not allowed

Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age

This FOA invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age. The activity would support aggregation of sufficient numbers of these individuals to advance the field's understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. **Application Due Date:** October 1, 2020

[RFA-AG-21-018 \(R24\)](#) clinical trial not allowed

Artificial Intelligence and Technology Collaboratories for Aging Research Coordinating Center (AITCC)

The AITCC will serve as a hub for the AITC program and will facilitate and coordinate trans-AITC activities. The AITCC will work closely with the NIA Program Officer (e.g., maintain a centralized database to track and synthesize progress and outcomes of each Collaboratory) and, in coordination with all AITC sites, will be responsive to requests generated by key AITC site personnel, NIA, NIH, the scientific community, and the general public. **Application Due Date:** October 1, 2020

[RFA-AG-21-011 \(R01\)](#) clinical trial optional

Central and Peripheral Control of Balance in Older Adults

This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is

critical for informing interventions and treatments for balance problems and falls in older adults. **Application Due Date:** October 2, 2020

[RFA-CA-19-034 \(P20\)](#) clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** October 18, 2020

[RFA-DA-21-009](#) R01 Clinical Trial Optional

Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents

The purpose of this funding opportunity announcement is to support (1) research to test the efficacy or effectiveness of interventions to prevent initiation and/or escalation of ENDS (electronic nicotine delivery system) use among adolescents; and (2) research on the impact of tobacco control policies, including ENDS-specific policies, on adolescent ENDS use behavior. For this funding announcement, individuals as young as 12 and as old as 18 encompass the core target age range. **Application Receipt Date:** October 19, 2020

November Due Dates

[RFA-AA-20-009](#) P01 Clinical Trial Optional

Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research

This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders. **Letter of Intent Due Date:** October 17, 2020 **Application Due Date:** November 17, 2020

[RFA-CA-20-004 \(R01\)](#); [RFA-CA-20-005 \(R21\)](#) clinical trial optional

Research Answers to NCI's Provocative Questions

These FOAs support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute Provocative Questions Initiative. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Please refer to the funding announcements for the updated list. **Application Due Dates:** November 17, 2020

[RFA-CA-20-007 \(R21\)](#) clinical trial optional

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management

This FOA invites applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** November 18, 2020

[RFA-CA-20-008](#) Early Stage Development (U01)

[RFA-CA-20-009](#) Advanced Development (U24)

[RFA-CA-20-010](#) Sustained Support (U24)

Informatics Technologies for Cancer Research and Management – clinical trial optional

The central mission of these FOAs is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Application Due Dates: November 18, 2020

[RFA-CA-20-052](#) U24 Clinical Trial Required

Limited Competition: Childhood Cancer Survivor Study

The purpose of this limited competition FOA is to continue support for the Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric and adolescent cancers. CCSS is a multi-institutional collaborative project that supports a participant cohort of over 25,000 five-year survivors of childhood cancer diagnosed between 1970-1999 and over 5,000 sibling control subjects.

LOI Due Date: October 18, 2020 **Application Due Date:** November 18, 2020

[RFA-HD-21-025](#) P30 Clinical Trial Not Allowed

[RFA-HD-21-026](#) P50 Clinical Trial Optional

Maternal and Pediatric Precision in Therapeutics (MPRINT)

This Funding Opportunity Announcements (FOAs) invites applications to form the Knowledge and Research Coordination Center (KRCC) and Centers of Excellence in Therapeutics (CETs) of the NICHD's Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will create a broadly accessible, integrated platform in maternal and

[RFA-AG-21-011 \(R01\)](#) clinical trial optional

Central and Peripheral Control of Balance in Older Adults

This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults. **Application Due Date:** October 2, 2020

[RFA-CA-19-034 \(P20\)](#) clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** October 18, 2020

November Due Dates

[RFA-AA-20-009](#) P01 Clinical Trial Optional

Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research

This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders. **Letter of Intent Due Date:** October 17, 2020 **Application Due Date:** November 17, 2020

[RFA-CA-20-004 \(R01\); RFA-CA-20-005 \(R21\)](#) clinical trial optional

Research Answers to NCI's Provocative Questions

These FOAs support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute Provocative Questions Initiative. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Please refer to the funding announcements for the updated list.

Application Due Dates: November 17, 2020

[RFA-CA-20-007 \(R21\)](#) clinical trial optional

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management

This FOA invites applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** November 18, 2020

[RFA-CA-20-008](#) Early Stage Development (U01)

[RFA-CA-20-009](#) Advanced Development (U24)

[RFA-CA-20-010](#) Sustained Support (U24)

Informatics Technologies for Cancer Research and Management – clinical trial optional

The central mission of these FOAs is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Application Due Dates: November 18, 2020

Multiple Due Dates

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: February 8, 2021, October 8, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees

pediatric therapeutics research to facilitate research, regulatory science, drug development, and synergy across the broader scientific community. **LOI Due Date:** October 30, 2020 **Application Due Date:** November 30, 2020

December Due Dates

[RFA-RM-20-015](#) U54 Clinical Trial Optional

[RFA-RM-20-016](#) U2R Clinical Trial Optional

[RFA-RM-20-017](#) U01 Clinical Trial Not Allowed

[RFA-RM-20-018](#) U2C Clinical Trial Not Allowed

Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Training Program

This Funding Opportunity Announcement (FOA) seeks applications for Research Hubs as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). DS-I Africa Research Hubs will be funded to advance data science health research and innovation in Africa and support new African and global partnerships that enhance the impact of data science health research. Applicants must propose at least 2 distinct research projects and a system for soliciting, evaluating, and awarding smaller pilots projects, all focused on a central health theme that addresses priorities in an African country or region. Applications must be submitted from African academic or other non-profit organizations. **LOI Due Date:** November 09, 2020 **Application Due Date:** December 08, 2020

[RFA-OH-21-003](#) U50 Research Project

Extension of the World Trade Center Health Registry

The purpose of this FOA is to extend and expand the World Trade Center Health Registry developed and managed by the New York City Department of Health and Mental Hygiene in a cooperative agreement with CDC. The new project will ensure ongoing data collection for victims of the September 11, 2001, terrorist attacks on the World Trade Center (WTC). The registry will continue to provide a central, unified database to assess short-term and long-term health effects among persons exposed to the WTC disaster. **Application Due Date:** December 11, 2020

[RFA-OH-21-004](#) R21 Exploratory/Developmental Research Grant

Exploratory/Developmental Grants Related to the World Trade Center Health Program

NIOSH supports exploratory and developmental research projects (R21) that address/mitigate/improve issues related to diagnostic or treatment uncertainty with respect to individuals, including enrolled World Trade Center (WTC) responder-sand certified-eligible WTC survivors, receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 health and Compensation Act (Public Law 111-347). **LOI Due Date:** November 06, 2020 **Application Due Date:** December 08, 2020

Multiple Due Dates

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** April 9, 2021, September 8, 2021

[RFA-NS-20-008 \(R41/R42\); RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\); RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** January 6, 2021, April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-HL-19-024 \(R25\)](#) clinical trial not allowed

Short-Term Research Education Program to Increase Diversity in Health-Related Research

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI.

Application Due Dates: February 26, 2021

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of

the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: October 9, 2020; February 10, 2021; June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: February 08, 2021, October 08, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: February 08, 2021, October 08, 2021, July 8, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

Application Due Dates: Monthly due dates starting November 1, 2019; please refer to the RFA.

[RFA-ES-20-015](#) R25 Clinical Trial Not Allowed

NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE)

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: **Courses for Skills Development.** The intent of this FOA is to encourage applications to develop and conduct short-term research education activities with the goal of improving knowledge and skills needed to conduct environmental health research. Short courses submitted under this FOA are expected to include relevant intensive hands-on training in environmental health science topics. In addition to in-person instruction, courses that incorporate innovative or novel education models, such as project-based learning or virtual instruction, are encouraged. **Application Due Dates:** November 30, 2020, November 29, 2021, November 28, 2022

[RFA-AG-21-021](#) K76 Clinical Trial Required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. LOI due 30 days before application due date. **Application Due Dates:** February 3, 2021, October 22, 2021, and October 21, 2022

Program Announcements Reviewed by an Institute (PAR)

[PAR-20-237](#) R01- Clinical Trial Optional

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations

This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups. **Application Due Date:** December 1, 2020

[PAR-20-278](#) R35 Clinical Trial Not Allowed

NCI Outstanding Investigator Award

This FOA invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their

lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. LOI Due Date: October 06, 2020 Application Due Date: November 06, 2020

[PAR-20-281](#) R01 Clinical Trial Optional

[PAR-20-282](#) R21 Clinical Trial Not Allowed

Fertility Status as a Marker for Overall Health

The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of the disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA. LOI required. Application Due Date: October 19, 2020, June 19, 2021, February 19, 2022, October 19, 2022, June 19, 2023

[PAR-20-254](#) Research R01 Clinical Trial Optional

[PAR-20-255](#) Exploratory/Developmental Research Grant R21 Clinical Trial Optional

[PAR-20-257](#) Small Research Grant R03 Clinical Trial Optional

Ethical, Legal and Social Implications (ELSI) Research

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. **Application Due Dates:** October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023

[PAR-20-294](#) U01 Clinical Trial Not Allowed

Core Infrastructure Support for Cancer Epidemiology Cohorts

This FOA is intended to support the basic maintenance activities of an existing CEC prospectively following: 1) study participants to examine associations between exposures and cancer incidence and/or outcomes or 2) cancer patients/survivors to examine exposures or factors associated with cancer progression, recurrence, mortality, incidence of new cancers, or other cancer/health-related outcomes. **Application Due Date(s):** November 12, 2020; April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022

[PAR-20-214](#) R21 Clinical Trials Optional

Research to Improve Native American Health

The purpose of this FOA is to support developmental/exploratory studies in preparation for health promotion, disease prevention, treatment, or treatment services research to improve health in Native American (NA) populations. **LOIs due** 30 days prior to the application due date. **Application Due Date(s):** May 17, 2021; May 17, 2022; May 17, 2023

[PAR-20-238](#) R01 Clinical Trial Optional

Intervention Research to Improve Native American Health

The purpose of this FOA is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. **LOIs due** 30 days prior to the application due date. **Application Due Date(s):** May 17, 2021; May 17, 2022; May 17, 2023

Individual Actions for Sustainability

Drive a fuel-efficient vehicle

Gas-smart cars, such as hybrids and fully electric vehicles, save fuel and money

